Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
PSA doubling time or PSADT is a valuable prognostic factor in assessing the need for second- or even third-line treatment in men with biochemical progression of prostate cancer.
Filed under: Living with Prostate Cancer, Management | Tagged: calculator, on-line, PSA doubling time, PSADT | 5 Comments »
A recent report in Cancer again seems to suggest that men with prostate cancer treated by radical prostatectomy (RP) who have a long time to biochemical recurrence (BCR) or a long PSA doubling time after BCR may have no higher overall risk of death than men who have no BCR at all.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: biochemical recurrence, mortality, PSA doubling time, radical prostatectomy | 1 Comment »
Researchers associated with the Duke Prostate Cancer have re-calibrated an older nomogram (used to predict the likelihood of biochemical recurrence after a radical prostatectomy or RP). The revised nomogram is now capable of predicting not only biochemical recurrence but also the much more clinically significant risk for an aggressive recurrence — in which the post-surgical [...]
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: aggressive, biochemical recurrence, PSA doubling time, PSADT, radical prostatectomy, surgery | Leave a Comment »
D’Amico and his colleagues demonstrated some time ago that PSA velocity and PSA doubling time (PSADT) are valuable tools in predicting which patients with recurrent prostate cancer after first-line treatment are at greatest risk of metastatic disease and prostate cancer-specific mortality. But they have now shown that PSADT is less predictive of risk in men [...]
Filed under: Management, Treatment | Tagged: comorbidity, PSA doubling time, PSA velocity, PSADT, recurrence | Leave a Comment »
A new study from a group at Duke University has attempted to assess whether data based on PSA doubling times in men with PSA levels up to 0.2 ng/ml can be used as effectively to make early treatment decisions for men with a rising PSA after first-line therapy as can PSA doubling times for men [...]
Filed under: Living with Prostate Cancer, Management | Tagged: early, PSA doubling time, PSADT, radical prostatectomy, salvage | Leave a Comment »
There has been an on-going difference of opinion within sections of the urology community regarding the value of PSA velocity and/or PSA doubling times in predicting outcomes to first-line prostate cancer treatment.
Filed under: Diagnosis, Management, Risk | Tagged: PSA doubling time, PSA velocity, risk | Leave a Comment »
We apologize to readers the lack of a weekend news report due to travel constraints, but this report will include all the past 3 days news that we are aware of, including: The relative value of PSAV and PSADT in predicting risk for positive results on rebiopsy Prostate size and brachytherapy Microspcopic bladder neck invasion [...]
Filed under: Diagnosis, Drugs in development, Management, Treatment | Tagged: bladder neck invasion, chemotherapy, prostate volume, PSA doubling time, PSA velocity | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site